2月17日,礼来(Eli Lilly)宣布,与澳大利亚制药公司 CSL 达成许可协议,获得其 IL‑6 抑制剂 clazakizumab 的部分权益。随着 IL‑6 成为心血管及炎症疾病领域日益热门的靶点,相关资产的竞争正在升温。去年 9 月,诺华以 14 亿美元 收购 Tourmaline Bio 获得其抗 IL‑6 单抗;Tiziana Life Science 也将其 IL‑6 资产分拆至...
Source Link2月17日,礼来(Eli Lilly)宣布,与澳大利亚制药公司 CSL 达成许可协议,获得其 IL‑6 抑制剂 clazakizumab 的部分权益。随着 IL‑6 成为心血管及炎症疾病领域日益热门的靶点,相关资产的竞争正在升温。去年 9 月,诺华以 14 亿美元 收购 Tourmaline Bio 获得其抗 IL‑6 单抗;Tiziana Life Science 也将其 IL‑6 资产分拆至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.